Tue. 9 Apr 2024, 4:01pm ET
Benzinga
Biotech, News, Events, General
For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year
Combination of IL-18 binding protein resistance with additional half-life enhancement to IL-18 variant demonstrated durable immunological effects in preclinical models
Data presented suggest dual-targeted, subunit approach to engineered IL-12 may mitigate cytokine's hallmark toxicity without compromising efficacy